Two years later, the combination of durvalumab (anti-PDL1) and tremelimumab (anti-CTLA4) was also approved by the FDA as a first-line treatment of unresectable HCC (without main portal vein invasion) based on the HIMALAYA study [15]. The gene discussed is CD274; the disease is hepatocellular carcinoma.